Valneva
Arnaud LEON, PhD has extensive work experience in the biopharmaceutical industry. Arnaud started their career at Vivalis in 2004 as a Junior Scientist and later became a Senior Scientist and Project Manager in Virology & Cell Culture. In 2013, they joined Valneva SE as a Group Leader in Vaccine Research & Discovery. Currently, Arnaud is serving as the Head of EB66 R&D at Valneva, where they are responsible for upstream process development, services activity, tech transfer, exploratory R&D, and pre-clinical studies for the production of virus-based bioproducts.
Arnaud LEON, PhD, completed their Master's degree in Cellular biology and Physiology at Rennes University from 1995 to 1997. Arnaud then pursued their PhD in Cellular Biology and Transgenesis at Nantes University in France from 2000 to 2004.
This person is not in any offices
Valneva
3 followers
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.